X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 99 filers reported holding X4 PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $155,577 | +3075.7% | 142,731 | +5552.7% | 0.00% | – |
Q2 2023 | $4,899 | -94.4% | 2,525 | -97.5% | 0.00% | – |
Q1 2023 | $87,000 | +443.8% | 100,000 | +949.9% | 0.00% | – |
Q3 2022 | $16,000 | +1500.0% | 9,525 | +684.0% | 0.00% | – |
Q2 2022 | $1,000 | -50.0% | 1,215 | -3.8% | 0.00% | – |
Q1 2022 | $2,000 | 0.0% | 1,263 | +89.1% | 0.00% | – |
Q4 2021 | $2,000 | +100.0% | 668 | +447.5% | 0.00% | – |
Q2 2021 | $1,000 | -97.1% | 122 | -96.9% | 0.00% | – |
Q1 2021 | $34,000 | -65.7% | 3,990 | -74.1% | 0.00% | – |
Q4 2020 | $99,000 | +32.0% | 15,422 | +38.3% | 0.00% | – |
Q3 2020 | $75,000 | +56.2% | 11,149 | +118.7% | 0.00% | – |
Q2 2020 | $48,000 | -48.4% | 5,098 | -45.1% | 0.00% | – |
Q1 2020 | $93,000 | -40.8% | 9,283 | -36.7% | 0.00% | – |
Q4 2019 | $157,000 | +36.5% | 14,668 | +61.9% | 0.00% | – |
Q3 2019 | $115,000 | +505.3% | 9,059 | +615.0% | 0.00% | – |
Q2 2019 | $19,000 | +533.3% | 1,267 | +663.3% | 0.00% | – |
Q1 2019 | $3,000 | – | 166 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tri Locum Partners LP | 6,247,500 | $6,809,775 | 2.18% |
Bain Capital Life Sciences Investors, LLC | 15,960,588 | $17,397,041 | 1.94% |
Stonepine Capital Management, LLC | 5,273,685 | $5,748,317 | 1.91% |
NEA Management Company, LLC | 14,986,793 | $16,335,604 | 1.26% |
Sio Capital Management, LLC | 2,599,003 | $2,832,913 | 0.88% |
New Leaf Venture Partners, L.L.C. | 335,000 | $365,150 | 0.47% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,973,683 | $2,151,314 | 0.25% |
Monashee Investment Management LLC | 427,265 | $465,719 | 0.20% |
Orbimed Advisors | 7,133,515 | $7,775,531 | 0.16% |
Parkman Healthcare Partners LLC | 800,000 | $872,000 | 0.16% |